Wolosker N, Munia MA, Rosoky R, Fidelis RJ, Nakano L, Kauffman P, Puech-Leão P.

Disciplina de Cirugia Vascular, Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil.
Abstract

OBJECTIVE: To study the results obtained with surgical treatment of patients with intermittent claudication (IC) who did not clinically improve with conservative treatment, accompanied by a long follow-up (average 6 years). METHODS: From January 1992 to January 2002, 26 patients treated surgically in a group of 1380 IC patient, representing 1.88% of the total. RESULTS: Sixteen patients did not experience walking limitations after the surgery. Nine patients improved, however, with some degree of limitation. No intraoperative mortalities occurred. Three patients experienced thrombosis of the treated artery 6, 48, and 60 months after the procedure and started to suffer IC with onset at the same distances as before the surgery. During the long-term follow-up, we observed a mortality rate of 23.0% due to myocardial infarctions (4 patients), renal insufficiency (1 patient), and cerebral infarction (1 patient). Two patients underwent coronary bypasses 2 and 4 years after the vascular surgery, and one underwent coronary angioplasty after 3 years of follow-up. The mean follow-up was 73 months. CONCLUSION: In our study, the results from surgical treatment of IC brought about a lasting regression of the ischemic conditions in a significant number of patients, with excellent patency rates (88.4%). We conclude that this is a good alternative for select patients, with low rates of complications and positive long-term results.

Surgical treatment for intermittent claudication in patients who do not improve with clinical treatment.
http://www.ncbi.nlm.nih.gov/pubmed/15340675
Arq Bras Cardiol. 2004 May;82(5):450-4, 445-9.

Síndrome do Desfiladeiro Torácico

Conheça o que é a Síndrome do Desfiladeiro Torácico, seus sintomas, testes e tratamentos.

Implantable Femoral Vein Catheters

Totally implantable femoral vein catheters in cancer patients. Eur J Surg Oncol.